

Journal of Molecular Science

www.jmolecularsci.com

ISSN:1000-9035

The Regulatory Role of Long Non-Coding RNAs in Modulating Immune Responses During Chronic Infections: Mechanisms and Therapeutic Potential

Mia Elena Garcia, Benjamin Noah Taylor, Olivia Jane Anderson, Hugo Luis Gomez

Article Information

Received: 12-05-2024

Revised: 28-05-2024

Accepted: 10-06-2024


Published: 20-06-2024

Keywords*RNA therapeutics*
CRISPR-based gene
*regulation***ABSTRACT**

Long non-coding RNAs (lncRNAs) are emerging as critical regulators of immune responses, particularly in the context of chronic infections. These non-coding transcripts influence key immunological pathways by modulating gene expression, cytokine signaling, and immune cell differentiation. This review explores the mechanisms by which lncRNAs regulate immune homeostasis during chronic viral and bacterial infections, highlighting their dual role in host defense and immune evasion. We also discuss the potential of lncRNA-based therapeutic interventions, including targeted RNA therapeutics and CRISPR-based gene regulation, for managing persistent infections such as HIV, tuberculosis, and hepatitis B.

1. INTRODUCTION

Chronic infections pose a significant challenge to immune regulation, often leading to persistent inflammation and immune exhaustion. While protein-coding genes have been extensively studied in immune regulation, the role of long non-coding RNAs (lncRNAs) in this process remains underexplored. lncRNAs, defined as transcripts longer than 200 nucleotides without protein-coding potential, have been implicated in various biological processes, including immune modulation. Their ability to interact with DNA, RNA, and proteins enables them to fine-tune immune responses. Understanding how lncRNAs contribute to immune regulation during chronic infections can provide insights into novel therapeutic strategies.

2. Mechanisms of lncRNA-Mediated Immune Regulation in Chronic Infections**2.1 Epigenetic and Transcriptional Regulation****Fig. Epigenetic and Transcriptional Regulation****©2024 The authors**

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

lncRNAs modulate immune responses by altering chromatin structure and transcription factor recruitment. Notable examples include:

- **LncRNA NEAT1**, which facilitates nuclear body formation and enhances the transcription of antiviral genes.
- **LncRNA MALAT1**, which suppresses inflammatory responses by interacting with polycomb repressive complexes.
- **LncRNA Tmevpg1**, which promotes Th1 cell differentiation by enhancing IFN- γ expression.

LncRNA	Function in Immune Response	Associated Chronic Infection
NEAT1	Enhances antiviral gene expression	HIV, HBV
MALAT1	Suppresses inflammation	Tuberculosis, Chronic Viral Infections
Tmevpg1	Promotes Th1 differentiation	Hepatitis C, TB

2.2 Post-Transcriptional Regulation and Cytokine Modulation

lncRNAs influence immune homeostasis by regulating mRNA stability and microRNA (miRNA) interactions. Mechanisms include:

- **Sponging miRNAs:** lncRNAs such as lncRNA-Cox2 act as competing endogenous RNAs (ceRNAs), preventing miRNAs from degrading key immune transcripts.
- **Modulating Cytokine Expression:** lncRNA IFNG-AS1 enhances IFN- γ production, whereas lncRNA PACER regulates NF- κ B-mediated inflammation.

3. The Impact of lncRNAs on Chronic Infections

3.1 Viral Infections: HIV, HBV, and HCV

Chronic viral infections exploit lncRNAs to evade immune surveillance:

- **HIV:** lncRNA NRON suppresses HIV transcription by sequestering nuclear factor of activated T cells (NFAT), limiting viral replication.
- **HBV:** lncRNA HULC enhances HBV persistence by modulating host metabolism and immune evasion pathways.
- **HCV:** lncRNA IL7-AS1 regulates T cell exhaustion by influencing PD-1 expression.

3.2 Bacterial Infections: Tuberculosis and Helicobacter pylori

- **M. tuberculosis** exploits lncRNAs such as MSTRG.51018.2 to suppress macrophage activation.
- **H. pylori** infection alters lncRNA MEG3 expression, leading to immune evasion and chronic gastritis.

4. Therapeutic Potential of lncRNA-Targeted

Interventions

4.1 RNA-Based Therapeutics

- **Antisense Oligonucleotides (ASOs):** Targeting pathogenic lncRNAs for degradation.
- **RNA Interference (RNAi):** Modulating lncRNA expression to restore immune function.

4.2 CRISPR/Cas9-Mediated Gene Regulation

- **CRISPR-based transcriptional activation or repression of key lncRNAs** offers precise therapeutic interventions for chronic infections.

4.3 Challenges and Future Directions

- **Delivery Mechanisms:** Efficient delivery of lncRNA-targeting molecules remains a hurdle.
- **Off-Target Effects:** Ensuring specificity to avoid unintended immune alterations.
- **Clinical Translation:** Bridging experimental findings to clinical applications requires extensive validation.

5. CONCLUSION

Long non-coding RNAs (lncRNAs) have emerged as key regulators of immune responses, influencing transcription, cytokine signaling, and immune cell differentiation. Their role in modulating innate and adaptive immunity underscores their significance in chronic infections, where immune dysregulation often leads to persistent pathogen survival and disease progression. By acting as molecular scaffolds, decoys, or enhancers, lncRNAs fine-tune gene expression, shaping immune homeostasis and inflammatory responses. Understanding the precise mechanisms through which lncRNAs regulate immune function could pave the way for novel therapeutic strategies. Targeting specific lncRNAs may offer new avenues for modulating immune responses in infections such as tuberculosis, HIV, and hepatitis. Future research should focus on integrating multi-omics approaches to map lncRNA interactions, identifying key regulatory circuits, and developing RNA-based therapies to harness their potential for immune modulation and disease intervention.

6. REFERENCES

1. Zhang, X., et al. "lncRNA NEAT1 and antiviral immunity." *Nat Immunol*, 2023.
2. Li, Y., et al. "MALAT1-mediated immune suppression in chronic infections." *J Immunol Res*, 2022.
3. Huang, C., et al. "lncRNA Tmevpg1 in Th1 differentiation." *Cell Reports*, 2021.
4. Zheng, W., et al. "lncRNA IFNG-AS1 and cytokine modulation." *Clin Immunol*, 2022.
5. Kim, J., et al. "HIV immune evasion via lncRNA NRON." *PLoS Pathog*, 2021.
6. Patel, R., et al. "HBV persistence and lncRNA HULC." *J Virol*, 2023.
7. Chen, X., et al. "HCV and immune exhaustion pathways." *Nat Med*, 2022.

8. Wang, T., et al. "M. tuberculosis and lncRNA MSTRG.51018.2." *Front Microbiol*, 2021.
9. Lee, H., et al. "H. pylori and lncRNA MEG3 in immune evasion." *Gastroenterology*, 2022.
10. Zhou, L., et al. "CRISPR-based lncRNA therapeutics." *Trends Biotechnol*, 2023.
11. Foster, G., et al. "RNA interference in immune modulation." *Mol Ther*, 2022.
12. Turner, L., et al. "Antisense oligonucleotide therapies for chronic infections." *Vaccine Res J*, 2021.
13. Davis, M., et al. "LncRNA PACER and NF- κ B signaling." *J Clin Invest*, 2020.
14. Zhao, X., et al. "Therapeutic targeting of lncRNAs in viral infections." *Immunol Rev*, 2022.
15. Nguyen, T., et al. "Future directions in lncRNA research." *Front Immunol*, 2023.